Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H22N2O3.2ClH |
Molecular Weight | 339.258 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC1=CC=C(CN2CCNCC2)C(OC)=C1OC
InChI
InChIKey=VYFLPFGUVGMBEP-UHFFFAOYSA-N
InChI=1S/C14H22N2O3.2ClH/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16;;/h4-5,15H,6-10H2,1-3H3;2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H22N2O3 |
Molecular Weight | 266.3361 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Trimetazidine is a medicine, which is used for the treatment of angina pectoris. The drug mechanism of action is explained by its ability to selectively inhibit long-chain 3-ketoacyl coenzyme A thiolase, an enzyme responsible for mitochondrial beta-oxidation of long chain fatty acids. Trimetazidine also increases pyruvate dehydrogenase activity, binds to the mitochondrial membrane, directly inhibits cardiac fibrosis and improves mechanical resistance of the sarcolemma.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P55084 Gene ID: 3032.0 Gene Symbol: HADHB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24902800 |
75.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VASTAREL Approved UseTrimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies. Launch Date1.34023676E12 |
PubMed
Title | Date | PubMed |
---|---|---|
The efficacy of medication on tinnitus due to acute acoustic trauma. | 2001 |
|
[Use of antioxidants and trimetazidine in preparation of patients with ischemic heart disease for coronary angiography]. | 2001 |
|
Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. | 2001 Dec |
|
Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model. | 2001 Dec |
|
Trimetazidine and reperfusion injury. | 2001 Jun |
|
The EMIP-FR Study: the evolution of scientific background as a non-controlled parameter. | 2001 Jun |
|
Trimetazidine for stable angina pectoris. | 2001 May |
|
Trimetazidine: stability indicating RPLC assay method. | 2001 May |
|
[Metabolic considerations in the treatment of coronary disease in diabetic patients]. | 2001 Nov |
|
Scavenger effect of experimental and clinically used cardiovascular drugs. | 2001 Nov |
|
[Significance of trimetazidine for out of hospital physical rehabilitation after myocardial infarction]. | 2002 |
|
Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. | 2002 |
|
Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? | 2002 Jan |
|
Determination of trimetazidine HCl by adsorptive stripping square-wave voltammetry at a glassy carbon electrode. | 2002 Jan 1 |
|
[The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow]. | 2002 Jul |
|
Last performance with VIAGRA: post-mortem identification of sildenafil and its metabolites in biological specimens including hair sample. | 2002 Mar 28 |
|
Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers. | 2002 Oct 4 |
|
[Effect of treatment with trimethazidine on characteristics of arrhythmia and indicators of heart rhythm in patients with chronic cardiac failure]. | 2003 |
|
Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. | 2003 Mar-Apr |
Patents
Sample Use Guides
The dose is one tablet of 20 mg of trimetazidine three times a day or 35 mg twice a day during meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9342596
Rat cardiomyocytes were treated with trimetazidine (1-5*10(-4) M final concentration) in the bath. Then the cells were submitted either to 150 min normoxia or to 150 min hypoxia followed by 90 min reoxygenation in the absence of oxidizable substrate. The drug (at 5*10(-4) M) was efficient in protecting the isolated cardiac myocytes against the functional alterations induced by substrate-free hypoxia and led thus to a better recovery upon reoxygenation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:26:15 UTC 2023
by
admin
on
Sat Dec 16 05:26:15 UTC 2023
|
Record UNII |
48V6723Z1P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
236-117-0
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
m11144
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL203266
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
SUB90444
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
DBSALT001114
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
100000091242
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
13171-25-0
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
759317
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
SUB12374MIG
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
48V6723Z1P
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
83201
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
DTXSID1045407
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | |||
|
235779
Created by
admin on Sat Dec 16 05:26:15 UTC 2023 , Edited by admin on Sat Dec 16 05:26:15 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity B = 0.55
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity F = 0.71
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity C = 0.37
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |